Source comparison
Combine BPC-157 GHK-Cu Synergy Dosing Timing: Protocol Comparison
This table compares three research-documented approaches to combine BPC-157 GHK-Cu synergy dosing timing, showing how different initiation sequences and dose escalations affect outcomes. Sequential (Standard) 250–350 mcg twice daily 1.5–2 mg once daily BPC-157
This comparison does not assign a generated winner or score.
- This table compares three research-documented approaches to combine BPC-157 GHK-Cu synergy dosing timing, showing how different initiation sequences and dose escalations affect outcomes.
- Sequential (Standard)
- 250–350 mcg twice daily
- 1.5–2 mg once daily
- BPC-157 days 1–7, add GHK-Cu day 8
- 6–8 weeks
- Most documented in literature; respects angiogenesis timeline; reduces risk of receptor saturation overlap
- Immediate Overlap (Acute)
- 350 mcg twice daily days 1–3, then 250 mcg twice daily
- 2 mg once daily starting day 4
- BPC-157 immediate, GHK-Cu after 72 hours
- 4–6 weeks
- Used for acute injury models; higher initial BPC-157 dose compensates for compressed timeline; GHK-Cu introduced before full vascular maturation
- Low-Dose Maintenance
- 200 mcg once daily
- 1 mg every other day
- Both start simultaneously after initial therapeutic course
- 8–12 weeks
- Post-recovery protocol; maintains tissue remodeling without receptor downregulation; total peptide load reduced by 60%
- High-Dose Short-Term
- 500 mcg twice daily
- 3 mg once daily
- Simultaneous start
- 3–4 weeks maximum
- Rarely used; risk of receptor desensitization and copper accumulation; no documented efficacy advantage over standard dosing